Data as of Q4 2025 (Dec 31, 2025)

Curanex Pharmaceuticals Inc

(CURX)

Financial Statements · SEC EDGAR XBRL

Net Income
-$4.2M
-1068.8%
EPS
$-0.17
-466.7%
Op. Income
-$4.2M
-1061.2%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
$3.0M
-
$4.2M
$365K
-$4.2M
-$365K
-$4.2M
-$362K
$-0.17
$-0.03
$-0.17
$-0.03
25.5M
13.3M